

Nectar Lifesciences Ltd.



Ref No. NLL/CS/2019- 87

Date: 14.08.2019

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Financial Results.

**Ref: Compliance Pursuant to Regulation 33 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Sir's,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone & Consolidated Financial results for the quarter ended June 30, 2019 which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours Sincerely,
For Nectar Lifesciences Limited


(Dr. Dinesh Datta)
Chief Executive Officer & Director

Encl: a.a.

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab -140507, Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email : cs@neclife.com, Website : www.neclife.com, [CIN: L24232PB1995PLC016664]



Statement of Financial Results for the Quarter ended 30.06.2019 (Rs in Lacs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19	30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
		Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
I	Income from Operations								
	Sales	64,313.25	88,021.74	59,493.82	311,492.29	63,891.47	87,735.39	59,299.40	311,285.78
	Less: GST Recovered	6,358.26	8,172.25	6,222.80	32,999.30	6,358.26	8,172.25	6,222.80	32,999.30
	Revenue from Operations	57,954.99	79,849.49	53,271.02	278,492.99	57,533.21	79,563.14	53,076.60	278,286.48
	Other operating Income	0.33	4.70	2.52	8.47	0.33	4.70	2.52	8.47
	Other Income	212.78	166.24	130.97	595.53	212.78	166.24	130.97	595.53
III	Total Income (I + II)	58,168.10	80,020.43	53,404.51	279,096.99	57,746.32	79,734.08	53,210.09	278,890.48
IV	Expenses								
	(a) Cost of Materials consumed	43,163.72	67,468.28	40,909.36	222,531.73	43,163.72	67,468.28	40,909.36	222,531.73
	(b) Purchase of Stock in Trade	468.15	1,133.07	322.18	4,281.71	468.15	1,133.07	322.18	4,281.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,127.39	(4,195.55)	(749.52)	(4,698.55)	676.40	(4,493.84)	(995.42)	(5,042.79)
	(d) Employee benefits expense	1,996.54	1,743.27	2,005.80	7,989.99	1,996.54	1,743.27	2,005.80	7,989.99
	(e) Finance costs	3,146.83	3,855.89	2,992.34	14,813.37	3,146.97	3,865.92	2,992.36	14,813.55
	(f) Depreciation and amortisation expense	1,640.35	1,454.15	1,629.31	6,325.74	1,640.35	1,454.15	1,629.31	6,325.74
	(g) Other expenses	5,020.35	6,268.51	4,777.91	21,997.79	5,029.43	6,278.83	4,821.50	22,108.54
	Total Expenses (IV)	56,563.33	77,737.62	51,887.38	273,241.78	56,121.56	77,449.68	51,685.09	273,008.47
V	Profit before exceptional items and tax (III- IV)	1,604.77	2,282.81	1,517.13	5,855.21	1,624.76	2,284.40	1,525.00	5,882.01
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	1,604.77	2,282.81	1,517.13	5,855.21	1,624.76	2,284.40	1,525.00	5,882.01
VIII	Tax Expense (1) Current Tax	245.09	275.22	144.58	741.47	245.09	275.22	144.58	741.47
	(2) Deferred Tax	9.49	266.88	52.10	380.56	9.49	266.88	52.10	380.56
IX	Profit for the period from continuing operations (VII-VIII)	1,350.19	1,740.71	1,320.45	4,733.18	1,370.18	1,742.30	1,328.32	4,759.98
	Other Comprehensive Income								
	Items that will not be reclassified subsequently to profit or loss								
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	2.60	-	2.60	-	2.60	-	2.60
	Items that will be reclassified subsequently to profit or loss								
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	22.51	-	22.51
	Total Other Comprehensive Income, (Net of Tax)	-	2.60	-	2.60	-	25.11	-	25.11
	Total Comprehensive Income for the period	1,350.19	1,743.31	1,320.45	4,735.78	1,370.18	1,767.41	1,328.32	4,785.09
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)								
	a) Basic	0.60	0.78	0.59	2.11	0.61	0.78	0.59	2.12
	b) Diluted	0.60	0.78	0.59	2.11	0.61	0.78	0.59	2.12



Notes

- 1 The above financial results were reviewed by Audit Committee on August 14, 2019 and approved by the Board in its meeting held on August 14, 2019. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2019.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.

Dated: 14.08.2019
Place: Chandigarh



By Order of the Board of Directors
of Nectar Lifesciences Limited
(Dr. Dinesh Dua)
Chief Executive Officer & Director

